Courageous Patients.Bold Effort.™

Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases.

We have four programs in our pipeline for the treatment of X-Linked Myotubular Myopathy (XLMTM), Pompe disease, CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) and Crigler-Najjar Syndrome (CN). We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

Audentes takes pride in strong, global relationships with the patient, research, medical and business communities with whom we share common interests. If you are a part of one of these communities please feel free to contact us.